Prior research on the early treatment of SSc with Tocilizumab, an interleukin-6 inhibitor, suggested that it would slow the progression of pulmonary involvement and stabilize pulmonary function; however, the primary endpoint of changing the mRSS relative to baseline was not met.[23]. Here, IL6 is linked to systemic sclerosis.